CVS Health: Options Hit 52-Week High as Earnings Land

CVS Health Corporation reported Q3 results on Wednesday, and the week's most telling signal is that options positioning reached its most defensive level of the past year on the day of the print, even as short sellers remain largely absent from the trade.

The options market is the standout this week. The put/call ratio climbed to 1.007, its highest reading of the past 52 weeks, against a 20-day average of 0.92. That puts the z-score at 1.80, the kind of reading that reflects genuine hedging demand rather than background noise. The move is a step change from where the ratio sat through most of October, when it ranged between 0.84 and 0.97. Short interest, by contrast, tells a much quieter story: at 1.2% of the free float, it has barely moved on the week, up just over 2%, and remains near the multi-month lows flagged in the earnings preview published earlier this week. Availability is essentially unlimited, with well over a billion shares available to lend and cost to borrow at 0.15%, down sharply from last week's elevated reading of 0.38%. There is no organised bearish positioning in the lending market. The options hedging and the short-interest calm are pulling in opposite directions, which is itself the story: investors wanted downside protection into the print without committing to a directional short.

The Street remains broadly constructive, though the most recent analyst action has been cautious at the margin. Leerink Partners cut its target to $112 from $119 in mid-October while keeping an Outperform rating, and UBS trimmed to $118 from $126 in early September, also maintaining Buy. Both moves happened after the stock had already recovered, suggesting analysts are trimming expectations rather than losing conviction. The mean price target of $115.52 sits about 26% above Wednesday's close of $91.41, an unusually wide gap that reflects how far the stock has come back from its lows without fully closing the discount the Street had priced in. Valuation remains undemanding: the trailing P/E is around 10.8x and EV/EBITDA sits near 9x, both modest for a company of CVS's scale. Factor scores are mixed but not alarming: earnings yield ranks in the 85th percentile, dividend score in the 94th, while the short score of 29 sits in the 74th percentile, consistent with low but slightly elevated bearish interest.

The bull and bear cases remain well-defined. Bulls point to the integrated model across retail pharmacy, PBM, insurance, and care delivery as a natural earnings stabiliser, with Oak Street adding longer-term upside and improving Healthcare Benefits margins narrowing the distance to target. Bears argue that all three core businesses face structural pressure simultaneously: PBM margins under competition and regulatory scrutiny, elevated medical benefit ratios in Medicare Advantage, and persistent reimbursement compression in retail pharmacy. The 2028 EPS target has already been trimmed, and around $250 million of Healthcare Benefits pressure tied to lost Stars bonus payments has been quantified. Neither side has a clean edge until the Q3 numbers are fully digested.

Ownership is concentrated and largely passive. BlackRock holds 9.6% of shares, Capital Research and Management 9.1%, and Vanguard 7.1%, with all three adding shares through the most recent reporting period. No 13D activist is on the register. The largest insider transaction in the visible window was a director-level open-market sale of roughly $34.6 million in May, which is now stale at over 130 days. There is no fresh insider signal to work with this week.

The stock gained 3.3% on Tuesday, the day before the earnings release, and is up 0.3% on the week, modest relative to the month's 5.7% gain. Close peers diverged on the day: UNH added 1%, HUM gained 1.8%, and CNC rose 1.4%, while DVA slipped 1.9%. CVS broadly tracked the managed care group rather than breaking out, which keeps the focus on what the Q3 print itself reveals about the medical cost and PBM dynamics the Street has been debating all quarter.

What to watch next is straightforward: how management characterises medical benefit ratio trends in Healthcare Benefits and whether the PBM margin commentary firms up or softens further, with the next scheduled earnings event now set for 10 February 2027.